An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients.

Autor: Saavedra, Danay1 (AUTHOR) danays@cim.sld.cu, Añé-Kourí, Ana Laura2 (AUTHOR), Sánchez, Naivy3 (AUTHOR), Filgueira, Lázaro Manuel4 (AUTHOR), Betancourt, Julio4 (AUTHOR), Herrera, Carlos4 (AUTHOR), Manso, Leniel4 (AUTHOR), Chávez, Elibet5 (AUTHOR), Caballero, Armando4 (AUTHOR), Hidalgo, Carlos3 (AUTHOR), Lorenzo, Geydi1 (AUTHOR), Cepeda, Meylan1 (AUTHOR), Valenzuela, Carmen1 (AUTHOR), Ramos, Mayra1 (AUTHOR), León, Kalet1 (AUTHOR), Mazorra, Zaima1 (AUTHOR), Crombet, Tania1 (AUTHOR)
Zdroj: Immunity & Ageing. 11/14/2020, Vol. 17 Issue 1, p1-8. 8p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje